Business Standard

EU: Malaria drugs used for virus could cause side effects

Image

AP London

The European Union's medicines regulator on Thursday warned countries that malaria drugs being used experimentally to treat the new coronavirus have potentially serious side effects, including seizures and heart problems.

The European Medicines Agency said in a statement that chloroquine and hydroxychloroquine two medicines embraced by US President Donald Trump and others as a potential COVID-19 treatment are known to cause heart rhythm problems, especially if combined with other drugs.

There is currently no licensed treatment for COVID-19 and dozens of trials are under way globally.

Chloroquine and hydroxychloroquine have long been used to treat malaria and anti-inflammatory diseases like rheumatoid arthritis.

In addition to the heart problems, the two drugs can also cause side effects including liver and kidney damage, seizures, and result in low blood sugar.

 

"Clinical data are still very limited and inconclusive, and the beneficial effects of these medicines in COVID-19 have not been demonstrated," the EMA said.

It noted that several clinical trials testing the drugs' effectiveness against the coronavirus are using higher than recommended doses, which it said could increase the risk of side effects including abnormal electric activity that could disrupt the heart rhythm.

Earlier this month, part of a study in Brazil was suspended after doctors found one quarter of patients taking chloroquine developed irregular heart rhythms after taking a higher dose.

The EMA reminded doctors and patients to report any suspected side effects from hydroxychloroquine and chloroquine to national authorities.

"These must not be used without a prescription and without supervision from a doctor," the agency said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 23 2020 | 8:34 PM IST

Explore News